Study name | Vaccine platform | Study characteristics | Treatment allocation | Number of participants (safety data) | Age (years) | Sex (male) | Race (white, black, Asian) | Countries | Comorbidities |
---|---|---|---|---|---|---|---|---|---|
Polack, 2020 [3] | mRNA | Primary analysis of safety and efficacy from the phase 2/3 part of BNT162b2 in preventing symptomatic COVID-19 in persons ≥16 years Median follow-up: 2 months | BNT162b2 (30 μg), 2 doses 21 days apart | 18,860 (21621) | 52a (Range; 16–89) | 51.1% | 82.9, 9.2, 4.2% | US 76.7%, Argentina 15.3%, Brazil 6.1% | Diabetes 8.3%, chronic lung disease 7.8%, cancers 3.9% |
Saline | 18,846 (21631) | 52a (Range; 16–91) | 50.1% | 82.9, 9.4, 4.3% | US 76.7%, Argentina 15.3%, Brazil 6.0% | Diabetes 8.4%, chronic lung disease 7.7%, cancers 3/5% | |||
Baden, 2020 [4] | mRNA | Primary analysis of safety and efficacy of phase 3 RCT in preventing COVID-19 in persons ≥18 years Median follow-up: 63 days | mRNA-1273 (100 μg), 2 doses 28 days apart | 15,170 (15166) | 51.3b (Range; 18–95) | 52.2% | 79.2, 10.3, 4.3% | US 100% | Diabetes 9.5%, severe obesity 6.8%, cardiac disease 5%, chronic lung disease 4.7% |
Saline | 15,181 (15185) | 51.4b (Range; 18–95) | 53.1% | 79.1, 10.1, 4.8% | US 100% | Diabetes 9.5%, severe obesity 6.7%, cardiac disease 4.9%, chronic lung disease 4.9% | |||
Sadoff, 2021 [5] | Adenoviral vector | Primary analysis of safety and efficacy of phase 3 RCT in preventing COVID-19 in persons ≥18 years Median follow-up: 58 days | Ad26.COV2.S (A single dose of 5 × 1010 viral particles) | 21,895 | 52a (Range; 19–100) | 55.1% | 58.7, 19.4, 3.4% | US 44.1%, Latin America 40.9%, South Africa 15.0% | Obesity 28.7%, hypertension 10.2%, diabetes 7.8% |
Saline | 21,888 | 52a (Range; 18–94) | 54.7% | 58.7, 19.5, 3.1% | US 44.1%, Latin America 40.9%, South Africa 15.0% | Obesity 28.4%, hypertension 10.5%, diabetes 7.7% | |||
Voysey, 2021 [6] | Adenoviral vector | Interim analysis of 4 cohorts of phase 1/2/3 RCT parts in preventing COVID-19 in persons ≥18 years Median follow-up: 3.4 months | ChAdOx1 nCoV-19 (2.2–6.5 × 1010 viral particles, 2 doses 4- ≥12 weeks apart) | 12,021 | Age (18–55 years) 81.5% | 44.2% | 75.1, 10.0, 3.7% | UK 50.0%, Brazil 41.6%, South Africa 8.4% | Cardiovascular disease 12.6%, respiratory disease 9.9%, diabetes 2.8% |
Meningococcal group A, C, W, and Y conjugate vaccine or saline | 11,724 | Age (18–55 years) 83.5% | 44.1% | 75.4, 10.2, 3.3% | UK 48.8%, Brazil 42.7%, South Africa 8.5% | Cardiovascular disease 12.0%, respiratory disease 10.0%, diabetes 2.5% | |||
Logunov, 2021 [7] | Adenoviral vector | Preliminary efficacy and safety analysis of phase 3 RCT in preventing COVID-19 in persons ≥18 years Median follow-up: 48 days | rAd26 (1st dose) and rAd5 (2nd dose) containing 1 × 1011 viral particles, 2 doses 21 days apart | 14,964 (16427) | 45.3b (SD 12.0) | 61.1% | 98.5%, NA, 1.5% | Russia 100% | Diabetes, hypertension, ischemic heart disease, obesity 24.7% |
Excipients | 4902 (5435) | 45.3b (SD 11.9) | 61.5% | 98.5%, NA, 1.5% | Russia 100% | Diabetes, hypertension, ischemic heart disease, obesity 25.2% | |||
Tanriover, 2021 [8] | Inactivated | Interim analysis of efficacy and safety of phase 3 RCT in preventing COVID-19 in persons aged 18–59 years Median follow-up: 43 days | CoronaVac (3 μg of SARS-CoV-2 virions), 2 doses 14 days apart | 6646 (6648) | 45a (IQR; 35–51) | 57.4% | NA | Turkey 100% | Hypertension 11.8%, diabetes 4.9%, chronic lung disease 2.9% |
Aluminium hydroxide diluent | 3568 (3568) | 45a (IQR;37–51) | 58.65 | NA | Turkey 100% | Hypertension, 11.6%, diabetes 4.5%, chronic lung disease 2.9% | |||
Palacios, 2021 [9] (preprint) | Inactivated | Interim analysis of efficacy and safety of phase 3 RCT in preventing COVID-19 in healthcare workers ≥18 years Median follow-up: 2 months after the second dose | CoronaVac (3 μg of SARS-CoV-2 virions), 2 doses 14 days apart | 6195 (6202) | 39.4b (SD 10.7) | 36.6% | 75.8, 5.3, 2.4% | Brazil 100% | Obesity 22.4%, cardiovascular disease 12.8%, diabetes 3.5% |
Aluminium hydroxide diluent | 6201 (6194) | 39.6b (SD 10.8) | 35.0% | 74.8, 5.2, 2.6% | Brazil 100% | Obesity 22.6%, cardiovascular disease 12.5%, diabetes 3.2% | |||
Heath, 2021 [10] | Protein subunit | Interim analysis of efficacy and safety of phase 3 RCT in preventing COVID-19 in persons ≥18 years Median follow-up: 66 days after the first dose and 45 days after the second dose | NVX-CoV2373 (5 μg), 2 doses 21 days apart | 7020 (7569) | 56a (18–84) | 51.4% | 94.4, 0.4, 2.9% | UK 100% | Chronic lung, cardiac, renal, neurologic, hepatic, immunocompromising conditions, and obesity 44.4% |
Saline | 7019 (7570) | 56a (18–64) | 51.7% | 94.5, 0.4, 3.0% | UK 100% | Chronic lung, cardiac, renal, neurologic, hepatic, immunocompromising conditions, and obesity 44.8% |